Panacea Biotec up 10% after Phase III enrolment for DengiAll dengue vaccine, target for 2027Panacea Biotec up 10% after Phase III enrolment for DengiAll dengue vaccine, target for 2027

Introduction

Leading biotechnology firm completed enrollment of 10,335 participants for Phase III trial of a tetravalent dengue vaccine, expected to become India’s first single-shot dengue vaccine by 2027.

Also Read: Sahaj Solar: Stock jump after reporting ₹198.21 Cr revenue in 9M FY26, growth 11.22%

Share price movement of Panacea Biotec

On January 8, 2026, Panacea Biotec Ltd opened at ₹402.90, up 5.14% from its previous close of ₹383.70. The stock reached a high of ₹422.30 (10.06%) and a low of ₹397.35 (3.57%). By 1:06 PM, it traded at ₹403.95, a 5.28% increase, with a market cap of ₹2,474.22 crore.

Panacea Biotec Completes Enrollment for DengiAll® Phase III Trial

Panacea Biotec Limited completed enrollment of 10,335 participants in the Phase III clinical trial of its tetravalent dengue vaccine, DengiAll®, conducted in collaboration with ICMR in India.

Participants will be monitored for two years to assess vaccine efficacy and immunogenicity. DengiAll® is expected to become India’s first indigenous single-shot dengue vaccine, with market entry anticipated by 2027.

Stock performance of Panacea Biotec for Period of 1 week, 6 months, and 1 year

Panacea Biotec Ltd delivered a 1.69% return over the past week, -7.71% over the past six months, and -14.3% over the past one year.

Also Read: Titan jumps 5% after strong 40% YoY growth in Q3 FY26, adds 56 stores

Shareholding pattern of Panacea Biotec

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	72.50%	72.50%	72.50%
FII	1.10%	0.80%	1.20%
DII	1.80%	2%	2%
Public	24.70%	25.20%	24.90%

About Panacea Biotec

Panacea Biotec Ltd (NSE: PANACEABIO), incorporated in 1984, develops, manufactures, and markets vaccines, pharmaceuticals, nutraceuticals, and nutrition products, supplying WHO-prequalified vaccines to over 50 countries.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs